Evidence map›Paper›PMID 37294386›Full record

ArticleAnnals of surgical oncology2023

Validation of the AJCC 8th Edition Staging System for Disseminated Appendiceal Cancer Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-institutional Analysis.

Gopika SenthilKumar, Anai N Kothari, Ugwuji N Maduekwe, Keith Fournier, Daniel E Abbott, Gregory C Wilson, Sameer H Patel, Jonathan Greer, Fabian Johnston, Sean P Dineen and 13 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 13 institutions in 1 country.

Gopika SenthilKumarDivision of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Anai N KothariDivision of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Ugwuji N MaduekweDivision of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Keith FournierDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Daniel E AbbottDivision of Surgical Oncology, Department of Surgery, University of Wisconsin, Madison, WI, USA.
Gregory C WilsonDepartment of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Sameer H PatelDepartment of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Jonathan GreerDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Fabian JohnstonDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Sean P DineenDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, and Department of Oncologic Sciences, Morsani College of Medicine, Tampa, FL, USA.
Benjamin D PowersDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, and Department of Oncologic Sciences, Morsani College of Medicine, Tampa, FL, USA.
Joel BaumgartnerDivision of Surgical Oncology, Department of Surgery, University of California, San Diego, CA, USA.
Jula VeerapongDivision of Surgical Oncology, Department of Surgery, University of California, San Diego, CA, USA.
Jennifer LeitingDivision of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN, USA.
Travis E GrotzDivision of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN, USA.
Shishir K MaithelDivision of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Charles StaleyDivision of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Mustafa RaoofDivision of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Laura LambertDepartment of Surgery, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.
Andrew LeeDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alex KimDivision of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Jordan M CloydDivision of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Harveshp MogalDepartment of Surgery, University of Washington Medical Center, Seattle, WA, USA. hmogal@uw.edu.ORCID http://orcid.org/0000-0001-5743-1424
Medical College of Wisconsin · USEmory University · USJohns Hopkins University · USMayo Clinic in Arizona · USMoffitt Cancer Center · USThe Ohio State University Wexner Medical Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of California San Diego · USUniversity of Cincinnati Medical Center · USCity Of Hope National Medical Center · USUniversity of Utah · USUniversity of Washington Medical Center · USUniversity of Wisconsin–Madison · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe AJCC 8th edition stratifies stage IV disseminated appendiceal cancer (dAC) patients based on grade and pathology. This study was designed to externally validate the staging system and to identify predictors of long-term survival.

methodsA 12-institution cohort of dAC patients treated with CRS ± HIPEC was retrospectively analyzed. Overall survival (OS) and recurrence-free survival (RFS) were analyzed by using Kaplan-Meier and log-rank tests. Univariate and multivariate cox-regression was performed to assess factors associated with OS and RFS.

resultsAmong 1009 patients, 708 had stage IVA and 301 had stage IVB disease. Median OS (120.4 mo vs. 47.2 mo) and RFS (79.3 mo vs. 19.8 mo) was significantly higher in stage IVA compared with IVB patients (p < 0.0001). RFS was greater among IVA-M1a (acellular mucin only) than IV M1b/G1 (well-differentiated cellular dissemination) patients (NR vs. 64 mo, p = 0.0004). Survival significantly differed between mucinous and nonmucinous tumors (OS 106.1 mo vs. 41.0 mo; RFS 46.7 mo vs. 21.2 mo, p < 0.05), and OS differed between well, moderate, and poorly differentiated (120.4 mo vs. 56.3 mo vs. 32.9 mo, p < 0.05). Both stage and grade were independent predictors of OS and RFS on multivariate analysis. Acellular mucin and mucinous histology were associated with better OS and RFS on univariate analysis only.

conclusionsAJCC 8

Indexed as

Appendiceal NeoplasmsHyperthermia, InducedPeritoneal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCytoreduction Surgical ProceduresHumansMucinsNeoplasm StagingRetrospective StudiesSurvival RateMucinsAJCC 8th EditionCytoreductive surgery and hyperthermic intraperitoneal chemotherapyDisseminated appendiceal cancer

Identifiers

PMID37294386
OpenAlexW4379967634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.